ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Generating real-world evidence in Alzheimer's disease: Considerations for establishing a core dataset.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review.Journal of clinical medicine · 2026Review
- Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.The international journal of neuropsychopharmacology · 2026Review
- Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Contextualizing Blood-Based Biomarkers for Dementia Globally.Journal of neurochemistry · 2026Review
- Eligibility for lecanemab treatment in a French memory clinic setting.Journal of neurology · 2026Observational
- Integrating real-world data with gold-standard longitudinal clinical and genomic data to advance precision medicine for the Alzheimer's Disease Research Center Program and beyond: a proof-of-concept data platform.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Classification and prediction of Alzheimer's disease stages and conversion from mild cognitive impairment based on multimodal data fusion.Frontiers in aging neuroscience · 2026Article
- Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health Plan.Journal of the American Geriatrics Society · 2025Article
- Everyday functioning in young onset dementia: differences between diagnostic groups.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Real-world brain imaging in a population-based cohort enables accurate markers for dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Donanemab: Appropriate use recommendations.The journal of prevention of Alzheimer's disease · 2025Article
- A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Article
- Generating real-world evidence in Alzheimer's disease: Considerations for establishing a core dataset.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Clinical staging in Swedish primary care using the Amsterdam Instrumental Activities of Daily Living Questionnaire.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Generating real-world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti-amyloid therapies.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Ongoing assessment of patients with Alzheimer's disease (AD) in postapproval studies is important for mapping disease progression and evaluating real-world treatment effectiveness and safety. However, interpreting outcomes in the real world is challenging owing to variation in data collected across centers and specialties and greater heterogeneity of patients compared with trial participants. Here, we share considerations for observational postapproval studies designed to collect harmonized longitudinal data from individuals with mild cognitive impairment or mild dementia stage of disease who receive therapies targeting the underlying pathological processes of AD in routine practice. This paper considers key study design parameters, including proposed aims and objectives, study populations, approaches to data collection, and measures of cognition, functional abilities, neuropsychiatric status, quality of life, health economics, safety, and drug utilization. Postapproval studies that capture these considerations will be important to provide standardized data on AD treatment effectiveness and safety in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.